手术移除 Essure® 植入物的长期有效性:回顾性队列研究

IF 2.1 4区 医学 Q2 OBSTETRICS & GYNECOLOGY European journal of obstetrics, gynecology, and reproductive biology Pub Date : 2024-10-29 DOI:10.1016/j.ejogrb.2024.10.047
Sébastien Insubri , Laure Bernard , Chrystèle Rubod , Michel Cosson , Marine Lallemant , Géraldine Giraudet
{"title":"手术移除 Essure® 植入物的长期有效性:回顾性队列研究","authors":"Sébastien Insubri ,&nbsp;Laure Bernard ,&nbsp;Chrystèle Rubod ,&nbsp;Michel Cosson ,&nbsp;Marine Lallemant ,&nbsp;Géraldine Giraudet","doi":"10.1016/j.ejogrb.2024.10.047","DOIUrl":null,"url":null,"abstract":"<div><h3>Study objective</h3><div>To assess symptom resolution and patient satisfaction following surgical explantation of Essure implants in the short and long term.</div></div><div><h3>Design</h3><div>Retrospective monocentric cohort study (Lille Regional University Hospital, France).</div></div><div><h3>Setting</h3><div>Essure is an implantable medical device for definitive sterilisation. Available from 2002, the Essure device has no longer been marketed since 2017. Following numerous reported side effects, the number of requests to withdraw Essure has steadily increased in recent years.</div></div><div><h3>Patients</h3><div>All women who underwent Essure removal between December 2016 and January 2020 to assess the benefits of surgery on these symptoms and patient satisfaction at 6 weeks and 6 months after the procedure.</div></div><div><h3>Interventions</h3><div>Removal of Essure implant with 4 types of surgery.</div></div><div><h3>Measurements</h3><div>The benefits of the surgery were assessed using data from the postoperative consultation 6 to 8 weeks after surgery and then from a telephone call 6 months after surgery.</div></div><div><h3>Main results</h3><div>86 patients were explanted during the study period. Surgery proved beneficial, with a complete reduction in symptoms at 6 months in 74 % of these patients. Many symptoms were relieved by surgery, with complete resolution of symptoms in 62 % of cases for muscle pain, in 69 % of cases for asthenia, in 82 % of cases for abdominal pain and 100 % of cases for menorrhagia. Patient satisfaction was high, with 97.3 % of patients willing to repeat the procedure and 95.95 % recommending it to a friend.</div></div><div><h3>Conclusion</h3><div>Removal of Essure implants in symptomatic patients appears to reduce all symptoms and improve quality of life in short and long term. Nevertheless, there are many symptoms associated with the insertion of Essure implants, and although surgery appears beneficial with good patient compliance, some adverse effects persist. It is therefore important to carry out a pre-operative etiological assessment and provide information on the risk of surgical failure.</div></div>","PeriodicalId":11975,"journal":{"name":"European journal of obstetrics, gynecology, and reproductive biology","volume":"303 ","pages":"Pages 212-217"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term effectiveness of surgical removal of Essure® implants: A retrospective cohort study\",\"authors\":\"Sébastien Insubri ,&nbsp;Laure Bernard ,&nbsp;Chrystèle Rubod ,&nbsp;Michel Cosson ,&nbsp;Marine Lallemant ,&nbsp;Géraldine Giraudet\",\"doi\":\"10.1016/j.ejogrb.2024.10.047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Study objective</h3><div>To assess symptom resolution and patient satisfaction following surgical explantation of Essure implants in the short and long term.</div></div><div><h3>Design</h3><div>Retrospective monocentric cohort study (Lille Regional University Hospital, France).</div></div><div><h3>Setting</h3><div>Essure is an implantable medical device for definitive sterilisation. Available from 2002, the Essure device has no longer been marketed since 2017. Following numerous reported side effects, the number of requests to withdraw Essure has steadily increased in recent years.</div></div><div><h3>Patients</h3><div>All women who underwent Essure removal between December 2016 and January 2020 to assess the benefits of surgery on these symptoms and patient satisfaction at 6 weeks and 6 months after the procedure.</div></div><div><h3>Interventions</h3><div>Removal of Essure implant with 4 types of surgery.</div></div><div><h3>Measurements</h3><div>The benefits of the surgery were assessed using data from the postoperative consultation 6 to 8 weeks after surgery and then from a telephone call 6 months after surgery.</div></div><div><h3>Main results</h3><div>86 patients were explanted during the study period. Surgery proved beneficial, with a complete reduction in symptoms at 6 months in 74 % of these patients. Many symptoms were relieved by surgery, with complete resolution of symptoms in 62 % of cases for muscle pain, in 69 % of cases for asthenia, in 82 % of cases for abdominal pain and 100 % of cases for menorrhagia. Patient satisfaction was high, with 97.3 % of patients willing to repeat the procedure and 95.95 % recommending it to a friend.</div></div><div><h3>Conclusion</h3><div>Removal of Essure implants in symptomatic patients appears to reduce all symptoms and improve quality of life in short and long term. Nevertheless, there are many symptoms associated with the insertion of Essure implants, and although surgery appears beneficial with good patient compliance, some adverse effects persist. It is therefore important to carry out a pre-operative etiological assessment and provide information on the risk of surgical failure.</div></div>\",\"PeriodicalId\":11975,\"journal\":{\"name\":\"European journal of obstetrics, gynecology, and reproductive biology\",\"volume\":\"303 \",\"pages\":\"Pages 212-217\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of obstetrics, gynecology, and reproductive biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0301211524005943\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of obstetrics, gynecology, and reproductive biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301211524005943","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究目的评估 Essure 植入物手术切除后的短期和长期症状缓解情况和患者满意度:设计:回顾性单中心队列研究(法国里尔地区大学医院):Essure 是一种用于最终绝育的植入式医疗设备。Essure 装置于 2002 年上市,自 2017 年起不再销售。据报道,Essure存在许多副作用,因此近年来要求撤回Essure的申请数量稳步上升:所有在 2016 年 12 月至 2020 年 1 月期间接受 Essure 移除手术的女性,以评估手术对这些症状的益处以及术后 6 周和 6 个月的患者满意度:干预措施:通过4种手术方式取出Essure植入物:通过术后6至8周的咨询数据和术后6个月的电话咨询数据评估手术的益处:主要结果:86 名患者在研究期间接受了手术。手术证明是有益的,其中 74% 的患者在术后 6 个月症状完全减轻。许多症状通过手术得到了缓解,62%的肌肉疼痛、69%的气喘、82%的腹痛和100%的月经过多症状完全消失。患者的满意度很高,97.3% 的患者愿意再次接受手术,95.95% 的患者向朋友推荐:有症状的患者移除 Essure 植入物似乎可以减轻所有症状,并在短期和长期内改善生活质量。尽管如此,植入 Essure 植入物后仍会出现许多相关症状,而且尽管手术在患者依从性良好的情况下似乎是有益的,但一些不良反应仍然存在。因此,进行术前病因评估并提供手术失败风险的信息非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Long-term effectiveness of surgical removal of Essure® implants: A retrospective cohort study

Study objective

To assess symptom resolution and patient satisfaction following surgical explantation of Essure implants in the short and long term.

Design

Retrospective monocentric cohort study (Lille Regional University Hospital, France).

Setting

Essure is an implantable medical device for definitive sterilisation. Available from 2002, the Essure device has no longer been marketed since 2017. Following numerous reported side effects, the number of requests to withdraw Essure has steadily increased in recent years.

Patients

All women who underwent Essure removal between December 2016 and January 2020 to assess the benefits of surgery on these symptoms and patient satisfaction at 6 weeks and 6 months after the procedure.

Interventions

Removal of Essure implant with 4 types of surgery.

Measurements

The benefits of the surgery were assessed using data from the postoperative consultation 6 to 8 weeks after surgery and then from a telephone call 6 months after surgery.

Main results

86 patients were explanted during the study period. Surgery proved beneficial, with a complete reduction in symptoms at 6 months in 74 % of these patients. Many symptoms were relieved by surgery, with complete resolution of symptoms in 62 % of cases for muscle pain, in 69 % of cases for asthenia, in 82 % of cases for abdominal pain and 100 % of cases for menorrhagia. Patient satisfaction was high, with 97.3 % of patients willing to repeat the procedure and 95.95 % recommending it to a friend.

Conclusion

Removal of Essure implants in symptomatic patients appears to reduce all symptoms and improve quality of life in short and long term. Nevertheless, there are many symptoms associated with the insertion of Essure implants, and although surgery appears beneficial with good patient compliance, some adverse effects persist. It is therefore important to carry out a pre-operative etiological assessment and provide information on the risk of surgical failure.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.60
自引率
3.80%
发文量
898
审稿时长
8.3 weeks
期刊介绍: The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the world.
期刊最新文献
Inside Back Cover - Editors with images Corrigendum to “Prophylactic tranexamic acid during myomectomy: A systematic review and meta-analysis of randomized controlled trials” [Eur. J. Obstet. Gynecol. Reprod. Biol. 276 (2022) 82–91] Survival outcomes of endometrial cancer patients with disease involving the lower uterine segment: A meta-analysis Outcomes of first assisted reproductive technology treatment in infertile women with and without antinuclear antibodies: A prospective cohort study Maternal and neonatal outcomes of prolonged second stage of labor with delayed pushing: A study of French Perinatal practices before and after guideline changes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1